CDAK / Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates

Codiak BioSciences (NASDAQ: CDAK ) stock is falling hard on Monday after the company announced plans for an asset sale through a Chapter 11 bankruptcy more_horizontal

Codiak BioSciences Inc. CDAK, -4.56% said Monday that it has field for bankruptcy, and it looking to selloff of its assets to maximize the company's v more_horizontal

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do t more_horizontal

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 61.54% and 701.52%, respectively, for the quarter ended June 2022. Do the more_horizontal

After losing some value lately, a hammer chart pattern has been formed for Codiak BioSciences, Inc. (CDAK), indicating that the stock has found suppor more_horizontal

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 27.18% and 69.43%, respectively, for the quarter ended December 2021. Do t more_horizontal

Codiak BioSciences, Inc. (CDAK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mi more_horizontal

Codiak BioSciences, Inc. (CDAK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mi more_horizontal